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Abstract
 
Abnormal proliferation of vascular smooth muscle cells
(VSMCs) contributes to intimal hyperplasia during athero-
sclerosis and restenosis, but the endogenous cell cycle regu-
latory factors underlying VSMC growth in response to arte-
rial injury are not well understood. In the present study, we
report that downregulation of cyclin-dependent kinase 2
(cdk2) activity in serum-deprived VSMCs was associated
with the formation of complexes between cdk2 and its inhib-
itory protein p27
 
KIP1
 
 (p27). Ectopic overexpression of p27 in
serum-stimulated VSMCs resulted in the inhibition of cdk2
activity and repression of cyclin A promoter activity. Collec-
tively, these findings indicate that p27 may contribute to
VSMC growth arrest in vitro. Using the rat carotid model of
balloon angioplasty, a marked upregulation of p27 was ob-
served in injured arteries. High levels of p27 expression in
the media and neointima correlated with downregulation of
cdk2 activity at 2 wk after angioplasty, and adenovirus-
mediated overexpression of p27 in balloon-injured arteries
attenuated neointimal lesion formation. Thus, the inhibition
of cdk2 function and repression of cyclin A gene transcrip-
tion through the induction of the endogenous p27 protein
provides a mechanism for the inhibition of VSMC growth at
late time points after angioplasty. (
 
J. Clin. Invest.
 
 1997. 99:
2334–2341.) Key words: restenosis
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Introduction
 
Atherosclerosis and restenosis are multifactorial processes
which result from a complex cascade of events involving
abnormal proliferation of vascular smooth muscle cells
(VSMCs)
 
1
 
 (1–5). Although the occurrence of restenosis in
 
z
 
 20–55% of patients after clinically successful revasculariza-
tion remains the major limitation to percutaneous transluminal
coronary angioplasty (6–11), no clinical trials have yet demon-
strated convincing effects in reducing the incidence of resteno-
sis (12–14). Previous studies using several models of angioplasty
have demonstrated a rapid proliferative response of VSMCs in
the media, followed by a second peak of proliferation in the
neointima, which then declines to basal levels by 2–4 wk after
angioplasty (15–18). While the contribution of several cell cy-
cle control genes and growth stimulatory genes to VSMC
growth has been well established (19–28), the endogenous fac-
tors underlying the reestablishment of the quiescent pheno-
type in VSMCs after angioplasty are largely unknown.
Cellular proliferation is controlled by multiple holoen-
zymes comprising a catalytic cyclin-dependent protein kinase
(cdk) and a cyclin regulatory subunit (29–33). Functional cdk/
cyclin holoenzymes phosphorylate target protein substrates
that facilitate progression through the cell cycle. cdk activity is
negatively regulated by the interaction with specific cdk inhibi-
tory proteins that cause cell cycle arrest in G
 
1
 
 phase when
overexpressed in transformed and nontransformed cell lines
(34–39). Mice lacking the cdk inhibitor function of p27 display
enhanced growth and multiple organ hyperplasia (40–42). In
addition to its role in the control of cell proliferation during
normal development, p27 appears to function as a tumor sup-
pressor (43), and reduced expression of p27 has been associ-
ated with poor cancer patient survival (44–46). In the present
study, we provide evidence suggesting the role of p27 as a neg-
ative regulator of VSMC growth in vitro and after angioplasty
in vivo.
 
Methods
 
Cell culture, adenovirus infection, and transient transfection assays.
 
Cells were incubated at 37
 
8
 
C in a humidified 5% CO
 
2
 
 95% O
 
2
 
 atmo-
sphere in media supplemented with 2 mM 
 
l
 
-glutamine, 200 U/ml peni-
cillin, 0.25 mg/ml streptomycin, and serum as indicated. Primary rat
aorta VSMCs were isolated essentially as described by Pickering et al.
(47) and maintained in DME supplemented with 10% FCS (growth
medium). To render cells quiescent, primary cultures were main-
tained for 3 d in DME supplemented with 0.5% FCS. Rat pulmo-
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1. 
 
Abbreviations used in this paper:
 
 Adp27, recombinant, replication-
defective adenovirus containing human p27
 
KIP1
 
 cDNA expression
cassette; Ad
 
b
 
gal, recombinant, replication-defective adenovirus con-
taining 
 
b
 
-galactosidase cDNA expression cassette; cdk, cyclin-depen-
dent kinase; VSMC, vascular smooth muscle cell; Xgal, 5-bromo-
4-chloro-3-indolyl-
 
b
 
-
 
d
 
-galactopyranoside.
 
 Inhibition of Neointima Formation by p27
 
KIP1
 
2335
 
nary arterial smooth muscle cells (PAC1) (48) were maintained in
medium 199 supplemented with 20% FCS.
Replication-defective adenoviruses directing expression of hu-
man p27 (Adp27) and 
 
b
 
-galactosidase (Ad
 
b
 
gal) under the transcrip-
tional control of the cytomegalovirus promoter have been described
previously (43). Primary cultures of rat aorta VSMCs were cultured in
growth medium to 
 
z
 
 60% confluence, and were incubated with the
indicated amounts of adenovirus for 24 h. Cells were then washed
with PBS and fed fresh growth medium. After an additional 16 h of
incubation, cells were harvested for the preparation of whole cell ex-
tracts for p27 immunoblot analysis and anti-cdk2 kinase assays (see
below).
PAC1 cells were transiently transfected using Lipofectamine re-
agent as recommended by the manufacturer (GIBCO Laboratories,
Grand Island, NY). Reporter vectors containing the 
 
2
 
356 to 
 
1
 
109
c-fos and 
 
2
 
79 to 
 
1
 
100 cyclin A gene 5
 
9
 
 flanking sequence upstream
from a promoterless luciferase cDNA, and the expression vector
pAC-CMV-p27, were provided by M. Simonson (Case Western
University, Cleveland, OH), J. Sobczak-Thepot (INSERM, Paris),
and J. Massagué (Memorial Sloan-Kettering Cancer Center, New
York), respectively. Transfection mixtures contained 36 
 
m
 
g of Lipo-
fectamine, 5 
 
m
 
g of reporter vector, 0–1 
 
m
 
g of pAC-CMV-p27, and
empty pAC-CMV plasmid to equalize the total amount of DNA. Dif-
ferences in transfection efficiency were corrected relative to the level
of alkaline phosphatase activity produced from cotransfected pSVA-
PAP plasmid (0.5 
 
m
 
g per transfection), which contains the reporter
gene under the control of the SV40 promoter/enhancer (49). Trans-
fected cells were maintained in medium 199 supplemented with 20%
FCS for 2 d, and then whole cell extracts were prepared to measure
luciferase and alkaline phosphatase activity as previously described (50).
 
Balloon injury in the rat carotid artery.
 
Balloon denudation of the
left common carotid artery in male Sprague-Dawley rats weighing
400–500 g was performed essentially as described by Clowes et al.
(16). Briefly, rats were anesthetized with an intraperitoneal injection
of sodium pentobarbital solution (45 mg/kg), the bifurcation of the
left common carotid artery was surgically exposed, and the left com-
mon and internal carotid arteries were temporarily ligated. A 2F em-
bolectomy catheter (Baxter Healthcare Corp., McGaw Park, IL) was
then introduced into the external carotid, and advanced to the distal
ligation of the common carotid. The balloon was inflated with saline
and drawn towards the arteriotomy site three times to denude the ar-
tery. After withdrawing the angioplasty catheter, the proximal exter-
nal carotid artery was permanently ligated, and blood flow was re-
stored to the common carotid artery by release of the ligatures. At
different time points after angioplasty, arteries were perfused in situ
with saline through a cannula inserted into the left ventricle, dissected
free of the surrounding tissue, snap-frozen, and stored at 
 
2
 
80
 
8
 
C until
the preparation of cell extracts (see below).
 
Preparation of cell extracts, Western blot analysis, and cdk2 kinase
assay.
 
Whole cell extracts from rat carotid arteries and cultured cells
were prepared in ice-cold lysis buffer (50 mM Hepes [pH 7.6], 150
mM NaCl, 2.5 mM EGTA, 1 mM EDTA, 10 mM 
 
b
 
-glycerophos-
phate, 0.1 mM NaVO
 
3
 
, 1 mM NaF, 0.1% Tween 20, 10% glycerol,
1 mM DTT, 1 mM PMSF, and 4 
 
m
 
g/ml leupeptin). Arterial extracts
were prepared using a homogenizer (Tissumizer Mark II; Tekmar
Co., Cincinnati, OH). Lysates were centrifuged at 4
 
8
 
C for 10 min in a
microfuge set at maximum speed, and the supernatant was stored at
 
2
 
80
 
8
 
C in small aliquots. The following dilutions of primary antibod-
ies were used for Western blot analysis: anti-p27 sc-528 (1:250), anti-
cdk2 sc-163 (1:500), and anti-cyclin E sc-481 (1:250) (Santa Cruz Bio-
technology, Santa Cruz, CA). Immunocomplexes were detected using
an ECL detection kit according to the recommendations of the manu-
facturer (Amersham Corp., Arlington Heights, IL). For cdk2-depen-
dent kinase assays, cell lysates (50–75 
 
m
 
g protein) were incubated at
4
 
8
 
C for 1.5–2 h under constant rotation in 0.5 ml of lysis buffer con-
taining 0.15 
 
m
 
g of anti–cdk2 antibodies and 25 
 
m
 
l of protein A/G
PLUS-Agarose beads (Santa Cruz Biotechnology). Immunocom-
plexes were washed three times with lysis buffer and twice with ki-
nase buffer (40 mM Tris-Cl [pH 7.6], 20 mM MgCl
 
2
 
, 2 mM DTT).
Subsequently, the beads were resuspended in 30 
 
m
 
l of kinase buffer
containing 2 
 
m
 
g of histone H1 (Boehringer Mannheim Biochemicals,
Indianapolis, IN), 7 
 
m
 
M ATP, and 5 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP. The reaction
mixtures were incubated at 30
 
8
 
C for 30 min and then separated on
12% SDS/polyacrylamide gels. Gels were stained with Coomassie
Blue (Sigma Chemical Corp., St. Louis, MO), dried, and autoradio-
graphed. Quantification of the signal was performed by counting indi-
vidual histone H1 bands in a scintillation counter. Background counts
per minute determined from regions of the dried gel that did not con-
tain protein were subtracted.
 
Immunohistochemistry.
 
Rat carotid arteries were fixed by im-
mersion in 100% methanol overnight, embedded in paraffin, and cut
in 5-
 
m
 
m sections for immunohistochemistry using a strepatavidin-per-
oxidase detection system according to the recommendations of the
manufacturer (Signet Laboratories Inc., Dedham, MA). Specimens
were incubated overnight at 4
 
8
 
C with anti-p27 mouse mAb (1:20 dilu-
tion) (Oncogene Research Products, Cambridge, MA). p27 immuno-
complexes were detected with AEC substrate (BioGenex Labs., San
Ramon, CA). Specimens were mounted with glycerol gelatin aqueous
mounting media (Sigma Chemical Co.) and examined on a micro-
scope (Vanox-T; Olympus Optical Co., Shinjuku, Japan). Pictures
were recorded on Kodak Gold Plus film (Eastman Kodak Co., Roch-
ester, NY).
 
Localized arterial infection with adenovirus vectors and quantifi-
cation of intimal hyperplasia.
 
Balloon injury in the rat carotid artery
was carried out as described above. After withdrawing the angio-
plasty catheter, Adp27 or Ad
 
b
 
gal was injected via a cannula inserted
just proximal to the carotid bifurcation. Viral infusion mixtures con-
tained 10 
 
m
 
l of adenovirus vector (total 0.5 
 
3
 
 10
 
9
 
 plaque-forming
units) and 90 
 
m
 
l of 15% (wt/vol) Poloxamer 407 (BASF Corp., Parsip-
pany, NJ). This pluronic gel has been shown to enhance adenovirus
infectivity in VSMC in vitro and after angioplasty in the rat carotid
artery (51, 52). The adenovirus solution was incubated for 20 min, af-
ter which the viral infusion was withdrawn, the cannula was removed,
and blood flow was restored. At 12 d after angioplasty, rats were
anesthetized and arteries were perfused in situ with saline followed
by 2% paraformaldehyde (in PBS) at a pressure of 90 mmHg through
a cannula inserted into the left ventricle. Tissues were immersed in
2% paraformaldehyde overnight, and were then embedded in paraf-
fin for tissue sectioning (see below). Cross sections (5-
 
m
 
m) were
stained with elastic-trichrome stain, and histological images were pro-
jected onto a digitizing board (Summagraphics Corp., Fairfield, CT).
Planimetric analysis of the projected sections was performed by a sin-
gle operator who was blinded to treatment group. A computerized
sketching program (MacMeasure Version 1.9; National Institute of
Mental Health, Bethesda, MD) was used to determine the medial, in-
timal, and luminal areas. For each artery, two sections from the mid-
dle third and two sections from one proximal third of the injured
segment (taken at least 100 
 
m
 
m apart) were analyzed. The four mea-
surements from each artery were averaged to determine the extent of
intimal lesion. Results were expressed as mean
 
6
 
SEM. Differences
between Adp27- and Ad
 
b
 
gal-infected arteries were analyzed using
an unpaired two-tailed Student’s 
 
t
 
 test.
Recombinant p27 and 
 
b
 
-galactosidase expression in injured arter-
ies was evaluated 3 d after angioplasty and adenovirus infection. Af-
ter perfusion with saline, two arteries were snap-frozen to examine
p27 expression by Western blot analysis (see above), and four arteries
were processed for evaluation of 
 
b
 
-galactosidase activity by his-
tochemical staining with the chromogenic substrate 5-bromo-4-chloro-
3-indolyl-
 
b
 
-
 
d
 
-galactopyranoside (Xgal). To obviate the issue of en-
dogenous 
 
b
 
-galactosidase activity (53), a modified adenovirus vector
containing nuclear localized 
 
b
 
-galactosidase cDNA expression cas-
sette under the control of the cytomegalovirus promoter was used for
these studies (courtesy of Didier Branellec, Rhône-Poulenc Rorer,
Vitry, France). Arteries for Xgal staining were fixed for 15 min by im-
mersion in 1% paraformaldehyde, rinsed with PBS and then incu-
bated overnight at 37
 
8
 
C in PBS, containing 5 mM K
 
4
 
Fe(CN)
 
6
 
, 5 mM
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K
 
3
 
Fe(CN)
 
6
 
, 2 mM MgCl
 
2
 
, 0.02% Nonidet P-40, 0.01% sodium deoxy-
cholate, and 1 mg/ml Xgal. Stained arteries were paraffin-embedded,
cut into 5-
 
m
 
m sections, mounted in microscope slides and counter-
stained with hematoxylin and eosin.
 
Results
 
Inhibition of cdk2 kinase activity by p27 in primary cultures of
VSMCs.
 
It has been demonstrated previously that cdk2 func-
tion is required for intimal smooth muscle cell accumulation
after angioplasty in the rat carotid artery (20, 23), and cdk2 ex-
pression correlates with VSMC proliferation after angioplasty
in both human and rat arteries (54). Therefore, the present
study aimed to investigate the mechanisms underlying the reg-
ulation of cdk2 activity in VSMCs. As shown in Fig. 1 
 
A
 
, cdk2
activity in primary cultures of VSMCs was markedly downreg-
ulated in serum-deprived cells (
 
Q
 
, quiescent), as compared to
asynchronously growing cells (
 
P
 
, proliferating), and quiescent
cells that had been serum-stimulated for 1 d (
 
SS
 
, serum-stimu-
lated). Abundant expression of both cdk2 and its regulatory
subunit cyclin E in serum-deprived VSMCs (Fig. 1 
 
B
 
) sug-
gested that the downregulation of cdk2 activity in these cells
was achieved posttranslationally. Thus, we examined the pat-
tern of expression of the cdk2 inhibitory protein p27 in cul-
tured VSMCs. While the total pool of p27 remained nearly un-
changed under all experimental conditions tested, p27 was
preferentially detected in anti-cdk2 immunoprecipitates har-
vested from serum-deprived VSMCs (Fig. 1 
 
B
 
). In marked
contrast, active cdk2 complexes in proliferating and serum-
stimulated VSMCs did not contain detectable levels of p27
(Fig. 1 
 
B
 
). These results suggest that p27 contributes to the in-
hibition of cdk2 activity in serum-deprived VSMCs.
Direct evidence for inhibition of cdk2 activity in VSMCs by
p27 was provided using an adenovirus vector system directing
the expression of p27 (Adp27). We demonstrated previously
that infection of tumor cells with Adp27 is associated with a
marked decrease in cdk2 kinase activity, inhibition of [
 
3
 
H]thy-
midine incorporation, and cell cycle arrest in G
 
1
 
 (43). Overex-
pression of p27 in VSMCs infected with Adp27 was demon-
strated by Western blot analysis, as compared to cells infected
with a control adenovirus encoding 
 
b
 
-galactosidase (Ad
 
b
 
gal)
(Fig. 2). Biological activity of overexpressed p27 protein was
demonstrated in anti-cdk2 immunoprecipitates, which re-
vealed low levels of cdk2-dependent kinase activity in Adp27-
infected cells (Fig. 2). Thus, these findings suggest that inhibi-
Figure 1. Cdk2 inactive complexes 
in serum-deprived VSMCs contain 
the inhibitory protein p27. Primary 
cultures of rat aorta VSMCs were 
maintained at subconfluent densi-
ties in 10% FCS (P, proliferating), 
at confluent densities for 3 d in 0.5% 
FCS (Q, quiescent), or serum stimu-
lated for 1 d with 10% FCS after 3 d 
of serum deprivation (SS, serum-
stimulated). (A) Histone H1 kinase 
activity was assayed in anti-cdk2 im-
munoprecipitates prepared from 
cell lysates (100-mg protein extract). 
Bars represent the mean6SEM of 
three independent assays. A repre-
sentative autoradiograph is shown. 
(B) Western blot analysis was per-
formed to determine the total 
amount of cdk2, cyclin E, and p27 
(75-mg protein extract). Analysis 
was performed three to four times using two different batches of lysates. Representative blots are shown. To investigate the association between 
cdk2 and p27, 0.75 mg of protein extract was first immunoprecipitated with anti-cdk2 antibodies, and then the immunoprecipitate was examined 
by Western blot analysis using p27 antibodies.
Figure 2. Adenovirus-mediated overexpression of p27 inhibits cdk2 
kinase activity in VSMCs. Primary cultures of rat aorta VSMCs were 
grown to z 60% confluence, and then infected with the indicated 
amounts of adenovirus directing the expression of p27 (Adp27) and 
b-galactosidase (Adbgal). After 40 h, cells were harvested for the 
preparation of whole-cell extracts. Expression of p27 was analyzed by 
Western blot. Note that the endogenous p27 is not detected under 
these conditions (15 mg of protein extract, 1-min exposure), as com-
pared to the analysis in Fig. 1 (75 mg of protein extract, 15-min expo-
sure). For cdk2 kinase assay, 50 mg of protein extract was immuno-
precipitated with anti-cdk2 antibodies.
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tion of cdk2 kinase activity by p27 contributes to VSMC
growth arrest in vitro.
 
p27 represses cyclin A promoter activity in VSMCs.
 
To test
whether p27 may limit VSMC growth through transcriptional
repression of positive regulators of cell cycle progression, we
next examined the effect of p27 on cyclin A promoter activity
in PAC1 cells. It has been demonstrated previously that cell
cycle regulation of the cyclin A gene promoter in NIH 3T3 fi-
broblasts is mediated by sequences extending from 
 
2
 
79 to
 
1
 
100 relative to the predominant transcription start site (55),
and binding of E2F to the 
 
2
 
37 to 
 
2
 
33 sequence is required for
this regulation (56). In agreement with these findings, tran-
sient transfection experiments demonstrated a marked down-
regulation of the 
 
2
 
79 to 
 
1
 
100 cyclin A promoter in serum-
deprived PAC1 cells relative to cells maintained in 20% FCS
(data not shown). Serum-dependent transactivation of the 
 
2
 
79
to 
 
1
 
100 cyclin A promoter fragment was inhibited by p27 in a
dose-dependent manner (Fig. 3). In marked contrast, p27 did
not affect activity from the 
 
2
 
356 to 
 
1
 
109 c-fos promoter, a
well-characterized serum-dependent gene that has not been
reported to be E2F responsive. Similar results were obtained
in 10T1/2 fibroblasts (data not shown).
 
Induction of p27 protein expression after angioplasty in the
rat carotid artery.
 
The results thus far suggest that inhibition
of cdk2 kinase activity and transcriptional repression of cyclin
A gene expression contributes to VSMC growth arrest in vitro.
To test whether p27 may limit VSMC growth in vivo, we exam-
ined its pattern of expression after angioplasty in the rat ca-
rotid artery. Western blot analysis disclosed a marked induc-
tion of p27 after balloon angioplasty (Fig. 4 
 
A
 
). Notably, high
levels of p27 correlated with downregulation of cdk2-associ-
ated kinase activity at 2 wk after injury (Fig. 4 
 
A
 
), coincident
with the termination of proliferation in this animal model of
vascular injury (16, 57). To examine the spatial pattern of ex-
pression of p27 after angioplasty in the rat carotid artery, we
performed immunohistochemical analysis. As compared to un-
injured arteries, p27 was abundantly expressed within the me-
dia and neointima at 2 wk after injury (Fig. 4 
 
B). At this time
point, expression of the phenotypic marker smooth muscle
a-actin was detected throughout the media and neointima
(data not shown). Taken together, these results suggested that
induction of p27 may contribute to the reestablishment of the
postmitotic state of VSMCs after angioplasty in the rat carotid
artery.
Localized arterial infection with Adp27 inhibits intimal
hyperplasia after angioplasty in the rat carotid artery. To test
directly whether p27 could inhibit neointima formation, we de-
livered Adp27 into the vessel wall of rat carotid arteries imme-
diately after balloon angioplasty. Injured arteries were also
treated with Adbgal control vector. Arteries were harvested 3 d
after adenoviral infection to examine expression of recombi-
nant p27 and b-galactosidase. The pooled tissue from two ar-
teries was used for Western blot analysis, which disclosed
higher levels of p27 in arteries infected with Adp27 as com-
pared to endogenous p27 in the Adbgal-infected group (Fig.
5 A). Evidence of b-galactosidase activity was evaluated using
Xgal histochemical staining and an adenovirus vector modified
to include a nuclear localization sequence. Gross examination
disclosed b-galactosidase activity over the entire length of
three out of four Adbgal-infected arteries (data not shown).
Microscopic examination of cross sections revealed dark blue
staining in the media of Adbgal-infected arteries which was
more intense in the nucleus (Fig. 5 B). Xgal staining was seen
not only in superficial but also in deeper cell layers of the me-
dia in Adbgal-infected arteries. Distribution of transfected
cells in cross sections was heterogenous, with positive regions
alternating with negative areas over the entire length of the in-
jured arterial segment. Analysis of three Adp27-infected arter-
ies disclosed undetectable b-galactosidase activity (Fig. 5 B).
Collectively, these data demonstrated successful adenovirus-
mediated overexpression of recombinant p27 and b-galactosi-
dase after angioplasty in the rat carotid artery.
In a second set of experiments, rats were killed 12 d after
adenoviral infection to perform quantitative morphometric
analysis on cross sections of the injured vessels. As shown in
Fig. 5 C, a significant reduction of 49% in the intimal to medial
area ratios was observed in Adp27-infected arteries (0.456
0.084), as compared to arteries infected with Adbgal (0.886
0.114, P 5 0.013 versus Adp27 group). Similarly, luminal nar-
rowing was reduced by 50% in the Adp27-infected arteries
(18.0863.84%) relative to Adbgal-treated vessels (35.956
4.75%, P 5 0.015 versus Adp27 group). These results demon-
strate that adenovirus-mediated overexpression of p27 after
angioplasty attenuates intimal hyperplasia in the rat carotid ar-
tery.
Discussion
Although the requirement of several positive regulators of
VSMC proliferation has been well established using different
Figure 3. p27 represses cyclin A promoter activity in VSMCs. PAC1 
cells were cotransfected with 5 mg of reporter vector (cyclin A or 
c-fos promoters cloned upstream of the promoterless luciferase 
cDNA), and with 0–1 mg of the expression vector pAC-CMV contain-
ing the p27 cDNA. Transfection mixes also contained empty
pAC-CMV vector to equalize the total amount of transfected DNA, 
and 0.5 mg of the alkaline phosphatase expression vector pSVAPAP. 
Cells were maintained in 20% FCS for 2 d, lysed, and assayed for lu-
ciferase activity, which was normalized relative to the alkaline phos-
phatase activity from the cotransfected internal control pSVAPAP 
vector. Normalized activity in the absence of p27 expression vector is 
defined as 100%. Values represent the mean6SEM of the indicated 
number of independent experiments (n). Statistically significant dif-
ferences relative to control are indicated (Student’s t test) (see 
Methods for details).
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models of angioplasty (19–28), the molecular basis of VSMC
growth arrest at late time points after angioplasty is poorly un-
derstood. The present study implicates the cdk inhibitory pro-
tein p27 as a negative regulator of VSMC growth in vitro and
after angioplasty in vivo. Inactive cdk2 complexes harvested
from serum-deprived VSMCs contained high levels of p27, as
compared to active cdk2 complexes isolated from serum-stim-
ulated cultures. Ectopic overexpression of p27 in VSMCs
downregulated cdk2 activity and repressed transcription from
the 279/1100 cyclin A promoter region, which contains an
E2F-binding site required for cell cycle–regulated cyclin A
gene expression (56). These data are consistent with recent
findings demonstrating the requirement of E2F for p27-depen-
dent repression of the 27300/111 cyclin A promoter in
NIH3T3 fibroblasts (58). Taken together with the requirement
of cdk2 and cyclin A for cell cycle progression (59–61), these
findings suggest the involvement of p27 as a mediator of
VSMC growth arrest in vitro. In this regard, evidence has been
presented recently suggesting that polymerized collagen inhib-
its VSMC proliferation in vitro through a2 integrin-mediated
upregulation of p27 (62). It is unclear why p27 preferentially
associated with cdk2 in serum-deprived VSMCs, even though
the total pool of p27 was not regulated by serum in cultured
VSMCs (Fig. 1 B). Others have suggested that increased asso-
ciation between p27 and cdk2 in MvLu mink epithelial cells
may be due to the release of p27 from cdk4/cyclin D com-
plexes (63, 64). Consistent with this notion, formation of cdk2/
p27 complexes in serum-deprived VSMCs correlated with a
marked downregulation of cdk4 and cyclin D1 protein levels
(data not shown).
We previously demonstrated a correlation between VSMC
proliferation and the expression of cdk2 and its regulatory sub-
units, cyclins E and A, after angioplasty in rat and human ar-
teries (54). The present study suggests that induction of the en-
dogenous p27 protein in the injured arterial wall may
contribute to the reestablishment of the quiescent phenotype
at late time points after angioplasty. Direct evidence implicat-
ing p27 as a negative regulator of VSMC proliferation after an-
gioplasty was provided using an adenovirus delivery system.
Overexpression of p27 after localized delivery of Adp27 to de-
Figure 4. Upregulation of p27 after angioplasty in the rat carotid artery. Cell extracts from uninjured (U) and injured arteries were prepared 
from the pooled tissue from 8 to 10 arteries at each time point. (A) Lysates were assayed for cdk2-dependent histone H1 kinase activity (75 mg) 
and p27 immunoblot (50 mg). Note that downregulation of cdk2 activity at 14 d after injury correlated with high levels of p27. (B) Immunostain-
ing for p27 in uninjured (left) and 14 d postinjured (right) arteries using a mouse mAb (a-p27). For control, primary antibody was omitted 
(2Ab). Note that the signal in the adventitia is nonspecific. Controls in which the biotinylated anti–mouse IgG was omitted revealed lack of spe-
cific p27 staining as well. Black and white arrowheads point to the internal and external elastic laminae, respectively.
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nuded arteries reduced neointima formation by 49% relative
to arteries infected with Adbgal control vector. Likewise, pre-
vious studies using adenovirus expression vectors for the
growth inhibitory retinoblastoma and p21 proteins have dem-
onstrated a z 50% reduction of intimal thickening after angio-
plasty in rat and porcine arteries (65–67). Conversely, human
cytomegalovirus-mediated inhibition of the tumor suppressor
protein p 53 may contribute to the development of restenosis
(68). Collectively, these studies support the notion that dereg-
ulated function of growth suppressor molecules affects VSMC
proliferation in vivo, thus suggesting novel strategies to pre-
vent restenosis.
In summary, the present study suggests a mechanism by
which suppression of cdk2 activity and transcriptional repres-
sion of cyclin A gene expression through upregulation of p27
may limit VSMC growth after angioplasty. Of note, p27- and
p21-dependent suppression of cyclin A, cdc2, E2F-1, and dihy-
drofolate reductase promoter activity has been recently dem-
onstrated in murine fibroblasts (58, 69, 70), and intimal cell
growth termination after angioplasty in porcine arteries was
associated with the induction of endogenous p21 (67). Eluci-
dating the signals underlying the upregulation of cdk inhibitors
and, ultimately, repression of cyclin gene expression at late
time points after angioplasty, should improve our understand-
ing of the pathobiology of restenosis.
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